Over the past roughly three years, AstraZeneca PLC’s key oncology drugs, including for lung cancer, have been facing gathering clouds in China.
Not only are Chinese homegrown rivals nibbling at market shares previously dominated by the UK major’s global blockbusters, but Chinese authorities appear to be closely
Key Takeaways
- On 30 October, AstraZeneca said in a statement that Leon Wang, its China president, is cooperating with an ongoing investigation by Chinese authorities.
- Over the past three years or so, the UK company's key oncology drugs, including those for lung cancer, have been facing stronger competition from homegrown Chinese rivals
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?